• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Dasatinib and blinatumomab treatment for acute lymphoblastic leukemia

byHarsh ShahandDeepti Shroff Karhade
October 31, 2020
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Treatment with dasatinib and blinatumomab was associated with high incidence of molecular response in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL).

2. Treatment with dasatinib and blinatumomab for patients with Ph-positive ALL was associated with a high incidence of survival.

Evidence Rating Level: 2 (Good)

Study Rundown: Prognosis for Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) in adults has improved since the introduction of ABL-specific tyrosine kinase inhibitors. The use of these therapeutics with a chemotherapy-free induction strategy requires a prephase treatment with glucocorticoids followed by an induction phase with a tyrosine kinase inhibitor plus glucocorticoids. This treatment strategy has resulted in greater percentage of patients having a complete hematologic response. As such, this trial evaluated a first-line tyrosine kinase inhibitor therapy in adults with newly diagnosed Ph-positive ALL. The therapy included induction with dasatinib, a second generation ABL tyrosine kinase inhibitor, followed by consolidation with blinatumomab, a bispecific anti-CD3 and anti-CD19 monoclonal antibody. The study results showed treatment with dasatinib and blinatumomab was associated with high incidence of molecular response and survival. This prospective cohort study was limited by the small patient population and the rapid acquisition of deleterious mutations amongst the cancer cells. Nonetheless, this study’s results are significant, and its findings highlight a chemotherapy-free induction strategy in the treatment of Ph-positive ALL.

Click to read the study in NEJM

Relevant Reading: Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

In-Depth [prospective cohort]: This prospective cohort study enrolled 63 patients as a part of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) cooperative trial group initiative. Patients included in the study were ≥18 years of age and newly diagnosed with Ph-positive ALL. Patients without molecular assay detection of the BCR-ABL1 fusion product were excluded from the study. Prephase glucocorticoid treatment lasted for seven days prior to patients receiving dasatinib. Glucocorticoid treatment continued for another 24 days prior to discontinuation on day 31. Dasatinib was administered at 140 milligrams once daily as induction therapy. Upon completion of the induction phase, blinatumomab was given at a dose of 28 micrograms per day for a minimum of two cycles. The primary end point was a molecular response defined by the BCR-ABL1 to ABL1 ratio at the end of the second blinatumomab cycle. The median age of the patients was 54 years (range, 24 to 82). At the completion of the induction period, 98% of the patients (62 of 63 patients) had a complete hematologic response defined as 5% bone marrow blasts or less, the absence of blasts in peripheral blood, no extramedullary involvement, and complete recovery of peripheral blood count. Additionally, 29% of the patients (17 out of 59 patients) had a molecular response at the end of the induction period, while 60% of patients (33 of 55 patients) had a molecular response at the time of the primary end point. The median follow-up was 18 months (range, 1 to 25). Overall survival was 95% (95% confidence interval [CI], 90 to 100) along with disease-free survival being 88% (95% CI, 80 to 97). Specifically, disease-free survival in patients with a molecular response at end of induction period was 100% compared to 85% of patients with a non-molecular response. Finally, longitudinal data was evaluated in 17 patients, which showed a decrease in the Tregs percentage and the CD4+/CD8+ ratio in patients receiving the third cycle of blinatumomab. The trends were maintained after the fourth and fifth cycles. Taken together, dasatinib and blinatumomab treatment in patients with Ph-positive ALL was associated with high incidence of molecular response and disease-free survival.

RELATED REPORTS

KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia

#VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute lymphoblastic leukemia (ALL)blinatumomabdasatinib
Previous Post

Microbleeds associated with increased risk of stroke

Next Post

HPV vaccination associated with substantial lower invasive cervical cancer risk

RelatedReports

Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors
Chronic Disease

KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia

August 17, 2021
#VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes
StudyGraphics

#VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes

February 19, 2021
Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors
Oncology

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

December 23, 2020
Next Post
2 Minute Medicine Rewind August 19, 2019

HPV vaccination associated with substantial lower invasive cervical cancer risk

Digital imaging detects sight-threatening retinopathy of prematurity

2 Minute Medicine Rewind November 2, 2020

Quick Take: Association of Cereal, Gluten, and Dietary Fiber Intake With Islet Autoimmunity and Type 1 Diabetes

IL-2 elevation after gluten exposure promising as a non-invasive diagnostic tool for Celiac Disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.